$AMD

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Dynatrace, Five Below, Fortune Brands, Klarna Group, Jersey Mike’s Subs, Moderna, Sherwin-Williams, and More

Wall Street analysts issued updates on several companies. AMD was upgraded to Strong Buy with a $641 target, while Five Below was downgraded to Hold. Bitcoin continued its rally, trading near $79,420. Investors await Fed comments and inflation data.

Original reporting
Published Aug 25, 2026, 11:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 2:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Dynatrace, Five Below, Fortune Brands, Klarna Group, Jersey Mike’s Subs, Moderna, Sherwin-Williams, and More — source image
Decision brief

The 30-second read

$AMDBullishMed
01

Why it matters

Collective analyst rating changes provide fresh signals for short-term positioning, though overall market sentiment remains mixed ahead of Fed commentary.

02

Market read

Analyst rating shifts can trigger immediate price moves, especially for high‑profile names like AMD and SHW.

03

What to watch

Potential macro headwinds from upcoming Fed data could dampen enthusiasm despite upgrades.

Relevance 5/10Novelty 5/10Timing: today

Background

Daily analyst research roundup highlighting upgrades, downgrades, and initiations across various US-listed stocks.

Company-level read

Ticker impact

$AMDBullishMedium confidence
Context

Upgraded to Strong Buy from Outperform with price target raised to $641.

Expected impact

Potential short-term upside of 3-5% on news flow.

Evidence & confidence

Upgrade from a reputable house with a higher target suggests near-term buying pressure.

$BFHBullishMedium confidence
Context

Upgraded to Outperform from Peer Perform with $130 target.

Expected impact

Modest upside of 1-2% expected.

Evidence & confidence

Target increase modest; market may price in gradually.

$DTBullishMedium confidence
Context

Upgraded to Overweight from Equal Weight, target raised to $65.

Expected impact

Potential 2-4% rally.

Evidence & confidence

Higher weight and target suggest bullish sentiment.

$MRNABullishLow confidence
Context

Raised to Peer Perform from Underperform, no target change.

Expected impact

Limited upside, 1-2% move.

Evidence & confidence

Rating lift without target indicates modest sentiment shift.

$FOURBullishMedium confidence
Context

Upgraded to Overweight from Equal Weight, target $59.

Expected impact

Potential 2-3% gain.

Evidence & confidence

Higher weight and target may attract short-term buying.

$FISBearishMedium confidence
Context

Downgraded to Equal Weight from Overweight, target $46.

Expected impact

Possible 2-4% decline.

Evidence & confidence

Downgrade suggests weaker expectations.

$FIVEBearishLow confidence
Context

Downgraded to Hold from Buy, target unchanged at $250.

Expected impact

Minor downside pressure.

Evidence & confidence

Hold rating may temper momentum.

$KLARBearishLow confidence
Context

Downgraded to Peer Perform from Outperform, no target.

Expected impact

Potential modest pullback.

Evidence & confidence

Rating cut without target suggests limited impact.

Market effects

Broad analyst activity may lift sentiment across tech, fintech, and consumer discretionary sectors.

US market focus; limited direct regional effect.

Minor global impact; primarily US equity investors.

Counterpoint

Some upgrades may be premature given macro uncertainty; caution on short-term trades.

Key entities

  • Raymond James

    Upgraded AMD to Strong Buy.

  • Wolfe Research

    Provided multiple upgrades/downgrades.

  • Morgan Stanley

    Upgraded Dynatrace.

Related articles

$MRKMedAI 8/10

Lisa Jarvis: A cancer vaccine is closer than ever

Merck & Co. and Moderna Inc. reported positive results from a Phase 3 trial of their mRNA cancer vaccine, intismeran, combined with Keytruda, showing efficacy in preventing melanoma recurrence. The vaccine uses mRNA to train the immune system to target cancer cells. Moderna's stock price more than doubled following the news, reflecting investor optimism about the potential of mRNA technology beyond infectious diseases.

$AMDMed

AMD's Next AI Accelerator Carries 432 Gigabytes of Memory -- 50% More Than the Last One. Here's the Bill That Comes With It.

AMD's new Instinct MI455X AI accelerator features 432GB of HBM4 memory, 50% more than its predecessor. The company compares it favorably to Nvidia's GPUs, citing higher memory capacity and performance. AMD's data center revenue surged 107% YoY to $6.7B in Q2, with strong demand for its Helios rack system. However, rising memory costs, with SK Hynix reporting a 76% operating margin, pose a challenge for AMD's margins.

$MRNAHighAI 9/10

Top Biopharma Analyst Sees Biotech M&A Market Reopening After a Long Freeze

Moderna (MRNA) and Merck (MRK) cancer vaccine reduced melanoma recurrence risk 49%, boosting MRNA +177% on readout. Revolution Medicines (RVMD) drug doubled pancreatic cancer survival, RVMD +163% YTD. AbbVie (ABBV) acquired Apogee for $10.9B. Barclays' Emily Field notes biotech M&A freeze is over, citing capital market reopening and oncology innovation.

$MRKLowAI 8/10

A cancer vaccine is closer than ever

Merck & Co. and Moderna Inc. reported positive results from a Phase 3 trial of their mRNA cancer vaccine, intismeran, combined with Keytruda, showing it delayed melanoma recurrence. Moderna's stock more than doubled on the news. The companies plan to share full data soon, and are testing the vaccine in other cancers. The trial marks a significant milestone for mRNA technology beyond infectious diseases.

$MRNAMedAI 8/10

Moderna (MRNA) Is Up 151.8% After First Positive Phase 3 mRNA Cancer Therapy Result - What's Changed

Moderna (MRNA) and Merck reported positive Phase 3 results for their mRNA cancer therapy, showing improved survival rates in melanoma patients. This marks the first successful Phase 3 outcome for an mRNA-based cancer treatment, potentially expanding Moderna's portfolio beyond vaccines. The company reaffirmed its 2026 revenue guidance, projecting $3.7 billion in revenue and $695.7 million in earnings by 2029.